Skip to main content

Table 1 Active clinical trials combining radiation with CTLA-4 inhibition

From: Current clinical trials testing the combination of immunotherapy with radiotherapy

NCT Number Phase Title Conditions Interventions RT Details Enrollment Sponsor/Collaborators
NCT01711515 Phase 1 Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer Cervical Cancer Cisplatin, Ipilimumab EBRT 6 weeks 28 National Cancer Institute (NCI)
NCT02406183 Phase 1 Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma Melanoma Ipilimumab SBRT 8-12 Gy × 3 fx 21 Radiotherapie|University Hospital, Ghent
NCT01935921 Phase 1 Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer Stage III-IVB Head and Neck Cancer Cetuximab, Ipilimumab IMRT, 7 wks 18 National Cancer Institute (NCI)
NCT02659540 Phase 1 A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma Melanoma Ipilimumab, Nivolumab EBRT 3 Gy × 10 fx or 9 Gy × 3 fx 18 Ludwig Institute for Cancer Research|Bristol-Myers Squibb
NCT01860430 Phase 1 A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer Head and Neck Cancer Ipilimumab, Cetuximab IMRT, 7 wks 18 University of Pittsburgh|National Cancer Institute (NCI)
NCT01996202 Phase 1 A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma Melanoma Ipilimumab EBRT 24 Duke University
NCT02311361 Phase 1 Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Pancreatic Cancer Tremelimumab, MEDI4736 SBRT, 1-5 fx 60 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
NCT02239900 Phase 1|Phase 2 Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors Liver cancer, Lung Cancer Ipilimumab SBRT 12.5 Gy × 4 fx 120 M.D. Anderson Cancer Center|Bristol-Myers Squibb
NCT02696993 Phase 1|Phase 2 Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer Brain Metastases (NSCLC) Nivolumab, Ipilimumab WBRT 3 Gy × 10 fx, SRS 1 fxa 80 M.D. Anderson Cancer Center|Bristol-Myers Squibb
NCT02254772 Phase 1|Phase 2 TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma B-cell Lymphoma Ipilimumab, TLR9 agonist SD-101 RT days 1, 2 27 Ronald Levy|National Cancer Institute (NCI)|Stanford University
NCT01565837 Phase 2 SART: Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma Melanoma Ipilimumab SBRT 1-5 fx 50 Wolfram Samlowski|Comprehensive Cancer Centers of Nevada
NCT01970527 Phase 2 Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Recurrent/Stage IV Melanoma Ipilimumab SBRT 3 fx 40  
NCT02107755 Phase 2 Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Melanoma Ipilimumab SBRT 32 Ohio State University Comprehensive Cancer Center|Bristol-Myers Squibb
NCT02097732 Phase 2 Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery Brain Metastases (Melanoma) Ipilimumab SRS 1 fxa 40 University of Michigan Cancer Center
NCT02115139 Phase 2 GRAY-B: GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases Melanoma Ipilimumab WBRT 3 Gy × 10 fx 66 Grupo Espanol Multidisciplinar de Melanoma|Bristol-Myers Squibb
NCT02701400 Phase 2 Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer Recurrent Small Cell Lung Cancer Tremelimumab, Durvalumab SBRT 20 Emory University|AstraZeneca
NCT02434081 Phase 2 NICOLAS: NIvolumab COnsolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC NSCLC Nivolumab EBRT 43 European Thoracic Oncology Platform|Bristol-Myers Squibb|Frontier Science Foundation, Hellas
NCT01449279 Pilot Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy Stage IV Melanoma Ipilimumab Palliative RT 20 Stanford University
  1. aDose determined by treating physician
  2. Abbreviations: Fx fraction, EBRT external beam radiation (standard fractionation), SBRT stereotactic body radiation therapy, SRS stereotactic radiosurgery, WBRT whole brain radiation therapy, NSCLC non-small cell lung cancer